SCHEMBL24424804

SCHEMBL24424804

COc1cnc(CO)c(C(F)(F)F)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.33
TSHR P16473 2/20 0.33
CYP11B2 P19099 1/20 0.33
ATF1 P18846 1/20 0.32
NFKB1 P19838 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
HPGD P15428 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DYRK3 O43781 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
DYRK1A Q13627 1/20 0.32
DYRK2 Q92630 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
XBP1 P17861 1/20 0.32
DPP4 P27487 1/20 0.32
SIRT6 Q8N6T7 1/20 0.32
HTT P42858 2/20 0.31
GAA P10253 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24424475 0.85 PDCD1 (0.35) KDM4ETSHRCYP11B2NPSR1HPGD
SCHEMBL24424803 0.77 PTGS1 (0.35)
SCHEMBL6056991 0.74 POLB (0.38) DPP4SIRT6
SCHEMBL24424815 0.73 SIRT6 (0.40) KDM4ETSHRATF1NFKB1SIRT6
SCHEMBL6056960 0.73 KDM4E (0.35) KDM4EMEN1KMT2ADPP4SIRT6
SCHEMBL24424828 0.72 TSHR (0.42) KDM4ETSHRHPGDMEN1KMT2A
SCHEMBL24423527 0.72 NPSR1 (0.41) KDM4EATF1NFKB1NPSR1KMT2A
SCHEMBL21055249 0.66 TSHR (0.39) KDM4ETSHRNPSR1MEN1KMT2A
SCHEMBL27989176 0.64 L3MBTL1 (0.46) KDM4ETSHRMEN1KMT2ASIRT6
SCHEMBL18975037 0.64 NPC1 (0.43) TSHRCYP11B2HPGDDPP4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD KDM4E 3945/4885TSHR 391/4885CYP11B2 26/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD KDM4E 2304/4885TSHR 142/4885CYP11B2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.